Viral transduction of the HER2-extracellular domain expands trastuzumab-based photoimmunotherapy for HER2-negative breast cancer cells (Q42174238)

18 October 2017

title

Viral transduction of the HER2-extracellular domain expands trastuzumab-based photoimmunotherapy for HER2-negative breast cancer cells (English)

1 reference

18 October 2017

1 reference

18 October 2017

Hiroshi Tazawa

0 references

Kyoko Shimoyama

1 reference

18 October 2017

Michihiro Ishida

1 reference

18 October 2017

Shinichiro Watanabe

1 reference

18 October 2017

Kazuhiro Noma

1 reference

18 October 2017

Kiyoto Takehara

1 reference

18 October 2017

Yuuri Hashimoto

1 reference

18 October 2017

Shunsuke Tanabe

1 reference

18 October 2017

Junji Matsuoka

1 reference

18 October 2017

Hisataka Kobayashi

1 reference

18 October 2017

Toshiyoshi Fujiwara

1 reference

18 October 2017

language of work or name

English

0 references

publication date

24 January 2015

1 reference

Breast Cancer Research and Treatment

18 October 2017

published in

1 reference

18 October 2017

volume

149

1 reference

18 October 2017

1 reference

18 October 2017

page(s)

597-605

1 reference

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

18 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Real-time monitoring of in vivo acute necrotic cancer cell death induced by near infrared photoimmunotherapy using fluorescence lifetime imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

In vivo breast cancer characterization imaging using two monoclonal antibodies activatably labeled with near infrared fluorophores

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Photochemical internalization (PCI): a technology for drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Photochemical internalization (PCI) of HER2-targeted toxins: synergy is dependent on the treatment sequence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

The effect of photoimmunotherapy followed by liposomal daunorubicin in a mixed tumor model: a demonstration of the super-enhanced permeability and retention effect after photoimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Strategies to Enhance Viral Penetration of Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

Non-viral vectors for gene-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3265-Y

10.1007/S10549-015-3265-Y

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

18 October 2017

1004640052

0 references

1 reference